Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Account Payables (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Change in Account Payables for 13 consecutive years, with -$5.1 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 180.23% to -$5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.6 million through Dec 2025, down 396.6% year-over-year, with the annual reading at -$19.6 million for FY2025, 396.6% down from the prior year.
  • Change in Account Payables hit -$5.1 million in Q4 2025 for Coherus Oncology, up from -$15.3 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $39.5 million in Q2 2024 to a low of -$50.4 million in Q3 2024.
  • Historically, Change in Account Payables has averaged -$170400.0 across 5 years, with a median of $409500.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: plummeted 1000.88% in 2021 and later skyrocketed 2243.35% in 2022.
  • Year by year, Change in Account Payables stood at -$29.6 million in 2021, then surged by 105.4% to $1.6 million in 2022, then tumbled by 149.03% to -$785000.0 in 2023, then soared by 907.9% to $6.3 million in 2024, then crashed by 180.23% to -$5.1 million in 2025.
  • Business Quant data shows Change in Account Payables for CHRS at -$5.1 million in Q4 2025, -$15.3 million in Q3 2025, and -$12.2 million in Q2 2025.